Back to Journals » Drug Design, Development and Therapy » Ten Years of Biosimilars in Europe
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (4278)
- Volume 18, 2024 (239)
- Volume 17, 2023 (283)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Journal Articles:
- Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System (1)
- Using Innovative Drug Delivery Systems to Improve the Efficacy and Applicability of Poorly Water-soluble Drugs (1)
- Advances in design and development of ophthalmic drugs (5)
- A cross-sectional survey on heart failure from China: disease burden and management (3)
- Ten Years of Biosimilars in Europe (4)
The European Medicines Agency defines a biosimilar as a biological medicine that is similar to another biological medicine already authorized for use. A regulatory framework to ensure high-quality biosimilars has been established in Europe since 2005 and is monitored and updated on an ongoing basis. The guiding principle of a biosimilar development program is to establish similarity between the biosimilar and the reference medicine by the best possible means, ensuring that the proven safety and efficacy of the reference medicine also applies to the biosimilar. The credibility of the scientific basis behind the biosimilar concept, and quality of regulatory decision-making, is demonstrated by the successful approval and clinical use of 20 biosimilar medicines since 2006 when Omnitrope® was the first biosimilar to be approved.
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M
Drug Design, Development and Therapy 2017, 11:1489-1495
Published Date: 16 May 2017
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M
Drug Design, Development and Therapy 2017, 11:1497-1503
Published Date: 16 May 2017
Ten years of biosimilar recombinant human growth hormone in Europe
Saenger P
Drug Design, Development and Therapy 2017, 11:1505-1507
Published Date: 16 May 2017
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
Schiestl M, Zabransky M, Sörgel F
Drug Design, Development and Therapy 2017, 11:1509-1515
Published Date: 16 May 2017